+

AU2024232125A1 - Compounds of drugs with an albumin binding moiety - Google Patents

Compounds of drugs with an albumin binding moiety

Info

Publication number
AU2024232125A1
AU2024232125A1 AU2024232125A AU2024232125A AU2024232125A1 AU 2024232125 A1 AU2024232125 A1 AU 2024232125A1 AU 2024232125 A AU2024232125 A AU 2024232125A AU 2024232125 A AU2024232125 A AU 2024232125A AU 2024232125 A1 AU2024232125 A1 AU 2024232125A1
Authority
AU
Australia
Prior art keywords
compounds
binding moiety
albumin binding
drugs
drug moieties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024232125A
Inventor
Nicola BISEK
Ulrike REISACHER
Kennett Sprogøe
Daniel STUBBA
Samuel WEISBROD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ascendis Pharma AS
Original Assignee
Ascendis Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma AS filed Critical Ascendis Pharma AS
Publication of AU2024232125A1 publication Critical patent/AU2024232125A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present application relates to compounds or pharmaceutically acceptable salts thereof, wherein the compounds comprise at least one polymeric moiety, to which at least two drug moieties are covalently and reversibly conjugated, which drug moieties are conjugated to an albumin binding moiety. The application also relates to pharmaceutical compositions comprising at least one such compound and their medical uses.
AU2024232125A 2023-03-06 2024-03-05 Compounds of drugs with an albumin binding moiety Pending AU2024232125A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP23160258 2023-03-06
EP23160258.2 2023-03-06
EP23195412.4 2023-09-05
EP23195412 2023-09-05
EP23203735 2023-10-16
EP23203735.8 2023-10-16
PCT/EP2024/055724 WO2024184351A1 (en) 2023-03-06 2024-03-05 Compounds of drugs with an albumin binding moiety

Publications (1)

Publication Number Publication Date
AU2024232125A1 true AU2024232125A1 (en) 2025-08-28

Family

ID=90365191

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024232125A Pending AU2024232125A1 (en) 2023-03-06 2024-03-05 Compounds of drugs with an albumin binding moiety

Country Status (4)

Country Link
AR (1) AR132067A1 (en)
AU (1) AU2024232125A1 (en)
TW (1) TW202440150A (en)
WO (1) WO2024184351A1 (en)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1225290A (en) 1968-06-21 1971-03-17
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
EP1620118B1 (en) 2003-04-08 2014-06-18 Yeda Research And Development Co., Ltd. Reversible pegylated drugs
JP4950022B2 (en) 2004-03-23 2012-06-13 コンプレックス バイオシステムズ ゲーエムベーハー Polymeric prodrugs with self-destructing linkers
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
KR20090055623A (en) 2006-09-15 2009-06-02 엔존 파마슈티컬즈, 인코포레이티드 Hindered Ester-Based Biodegradable Linkers for Oligonucleotide Delivery
CA2693616A1 (en) 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery system containing a multi-substituted aromatic moiety
EP3981761A3 (en) 2008-02-01 2022-08-24 Ascendis Pharma A/S Intermediates for prodrugs
CA2723263A1 (en) 2008-05-23 2009-11-26 Enzon Pharmaceuticals, Inc. Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
WO2011082368A2 (en) 2009-12-31 2011-07-07 Enzon Pharmaceuticals, Inc Polymeric conjugates of aromatic amine containing compounds including releasable urea linker
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
DK2566335T3 (en) 2010-05-05 2016-10-03 Prolynx Llc Controlled release of active ingredients from macromolecular CONJUGATES
WO2011140392A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from solid supports
EP2741744A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
US11633487B2 (en) 2014-08-06 2023-04-25 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
SG11201908547VA (en) 2017-03-22 2019-10-30 Genentech Inc Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
CN112955216A (en) * 2018-09-12 2021-06-11 奎亚培格制药公司 Releasable GLP-1 conjugates
CA3114272A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
EP3856255A1 (en) * 2018-09-26 2021-08-04 Ascendis Pharma A/S Treatment of infections
EP3946460A4 (en) 2019-04-05 2023-03-29 Prolynx LLC IMPROVED CONJUGATIONAL LINKERS
BR112022024058A2 (en) 2020-05-26 2022-12-20 Univ Indiana Res & Tech Corp PTH ANALOGS FOR THE TREATMENT OF HYPOPARATHYROIDISM
US20250268986A1 (en) 2020-11-06 2025-08-28 Novo Nordisk A/S Glp-1 prodrugs and uses thereof
KR102691149B1 (en) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 Compositions and methods for treating metabolic and liver diseases
AU2022347024A1 (en) 2021-09-15 2024-05-02 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders

Also Published As

Publication number Publication date
WO2024184351A1 (en) 2024-09-12
TW202440150A (en) 2024-10-16
AR132067A1 (en) 2025-05-21

Similar Documents

Publication Publication Date Title
Kumar et al. Structural hybridization as a facile approach to new drug candidates
EP4374927A3 (en) Saponin conjugates
WO2004082628A3 (en) Improved bioavailability and improved delivery of acidic pharmaceutical drugs
EP1148053A4 (en) 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
WO2003013609A1 (en) Sustained-release medicines
WO2007004236A3 (en) Improved drug or pharmaceutical compounds and a preparation thereof
WO2010033733A4 (en) Folate receptor binding conjugates of antifolates
JP2000159790A5 (en)
IL294247B1 (en) (4r,2r)-1-(3-chloro-2-fluorobenzyl)-4-((5-fluoro-4-methyl-6-((5-methyl-h1-pyrazol-3-yl)amino)pyridin-2-yl)methyl)-2-methylpiperidine-4-carboxylic acid and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt thereof
IL278717B1 (en) Initial dose of PTH conjugates
HK1042303A1 (en) New compounds
WO2024099364A3 (en) Fused multicyclic compounds and their use as parp1 inhibitors
CA2445478A1 (en) Retinol derivatives potentiation of active substances by micellar preparation
MX2022016263A (en) Cyclobutyl-urea derivatives.
WO2001052896A3 (en) Compositions with enhanced oral bioavailability
AU2024232125A1 (en) Compounds of drugs with an albumin binding moiety
EP1426360A4 (en) 2-PHENYL-3-HETEROARYL PROPIONIC ACID DERIVATIVES AND THEIR SALTS, AND MEDICAMENTS CONTAINING THEM
Nudelman Mutual Prodrugs-Codrugs
WO2005027828A3 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
WO2023275413A3 (en) Solid pharmaceutical formulations of varenicline
BR0013265A (en) Compound, use of a structural element, drug, pharmaceutical preparation for oral or parenteral use, and use of the compound
AU2024210943A1 (en) Prmt5 inhibiting compounds and uses thereof
EP0745390A3 (en) Polymeric prodrugs for beta-lactamase and uses thereof
Chauhan et al. Dendrimers for drug solubilization, dissolution and bioavailability
HRP20090022T3 (en) PHARMACEUTICAL PREPARATIONS CONTAINING ASCORBINIC ACID FOR THE TREATMENT OF Fungal SUPERINFECTIONS AND Fungal Relapses
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载